参考文献: [1] Mahmoud A, Almohtasib Y, Naeem A, et al. Abstract 4138221: Ezetimibe plus statin combination vs. double dose statin for patients with dyslipidemia and ASCVD risk: A Systematic Review and Meta-Analysis [...
users, despite adjustment including HDL-C.#Many US adults with borderline levels of TGs are at elevated ASCVD risk despite statin therapy, suggesting the need first for greater lifestyle modification efforts, and when indicated, evidence-based therapies known to reduce this residual ASCVD risk.doi...
41. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P,Koprowicz K, McBride R, Teo K, Weintraub W; AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive st...
Background:Dyslipidemia is a major risk factor for Atherosclerotic Cardiovascular Disease (ASCVD). Statin is a crucial intervention to fix dyslipidemia and reduce the ASCVD risk. Still, there are several regimens to achieve blood lipid level targets, including increasing the statin dose or adding ezet...
Statin High-intensity statin PCSK9 Alirocumab Evolocumab Bempedoic acid Icosapent Ethyl Inclisiran Obicetrapib Zerlasiran Combination therapy Aspirin Immunotherapy Short interfering RNA (siRNA) Diabetes Risk Factors and Prevention CVD Risk Factor Primary prevention Prevention Risk assessment Menopause ...
The manuscript is in the pipeline but if people were not on statin or the lower dosage, over a half of the patients got greater than 30% reduction. This is a viable option.The reason I bring that up is the OUTCOMES trial is being done in patients who are statin intolerant. In other ...
The absolute risk reduction in patients with diabetes and CKD was substantial, yielding a number needed to treat of 14 to prevent 1 major cardiovascular event over 4.8 years. Both treatments were well tolerated.CONCLUSION: Patients with diabetes, stable coronary artery disease, and mild to moderate...
ASCVD Risk Refinement With NT-proBNP for Statin Allocation Among Low- and Intermediate-Risk Individualsdoi:10.1161/CIRCULATIONAHA.124.071071atherosclerotic cardiovascular diseaseepidemiologyN-terminal pro-B-type natriuretic peptidepopulation-basedprimary prevention...
ASCVD Risk and Statin Use in PADatherosclerosiscardiovascular diseasecardiovascular eventshydroxymethylglutaryl-CoA reductase inhibitorsperipheral artery diseasesecondary preventiondoi:10.1016/j.jacc.2020.06.009Marc P. BonacaConnie N. HessJournal of the American College of Cardiology...
以ODYSSEY EAST[3]、OPT-BIRISK研究[4]为例,韩雅玲院士全面介绍了我国近年相关临床研究所取得的成就,并提出了建立临床研究合作体系的建议,旨在促进中国临床研究水平的整体提升,造福广大患者。 左:首都医科大学附属北京安贞医院 马长生教授;右:暨...